XEPI Drug Patent Profile

When do Xepi patents expire, and what generic alternatives are available?

Xepi is a drug marketed by Lnhc and is included in one NDA. There are two patents protecting this drug.

The generic ingredient in XEPI is ozenoxacin. There is one drug master file entry for this compound. Additional details are available on the ozenoxacin profile page.

DrugPatentWatch^® Generic Entry Outlook for Xepi

Xepi was eligible for patent challenges on December 11, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 15, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for XEPI

US Patents:	2
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	62
Patent Applications:	167
What excipients (inactive ingredients) are in XEPI?	XEPI excipients list
DailyMed Link:	XEPI at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for XEPI

NDA:

208945

Dosage:

CREAM;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for XEPI

XEPI is protected by two US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lnhc	XEPI	ozenoxacin	CREAM;TOPICAL	208945-001	Dec 11, 2017		DISCN	Yes	No
Lnhc	XEPI	ozenoxacin	CREAM;TOPICAL	208945-001	Dec 11, 2017		DISCN	Yes	No			Y

Expired US Patents for XEPI

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lnhc	XEPI	ozenoxacin	CREAM;TOPICAL	208945-001	Dec 11, 2017

International Patents for XEPI

When does loss-of-exclusivity occur for XEPI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Cyprus

Denmark

European Patent Office

Hong Kong

Japan

Mexico

Netherlands

Philippines

Poland

Portugal

Russian Federation

Slovenia

South Korea

Spain

Taiwan

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering XEPI around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	342897
Brazil	9909456
Canada	2327328	DERIVES D'ACIDE QUINOLONECARBOXYLIQUE OU SELS DE CEUX-CI (QUINOLONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF)

Supplementary Protection Certificates for XEPI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2344130	300884	Netherlands		PRODUCT NAME: OZENOXACIN; REGISTRATION NO/DATE: ES/H/414/1/DC 20170519
2344130	122017000073	Germany		PRODUCT NAME: OZENOXACIN; NAT. REGISTRATION NO/DATE: 97303.00.00 20170803; FIRST REGISTRATION: BELGIEN BE509591 20170517
2344130	2017C/031	Belgium		PRODUCT NAME: OZENOXACINE; AUTHORISATION NUMBER AND DATE: BE509591 20170519

XEPI (Ozenoxacin) Market Dynamics, Financial Trajectory, Patent Status and Generic Risk

Last updated: September 30, 2026

XEPI is a low-volume prescription topical antibiotic containing ozenoxacin 1% cream. The FDA approved it in December 2017 for impetigo caused by susceptible strains of Staphylococcus aureus or Streptococcus pyogenes in patients aged two months and older.[1] Its commercial opportunity is limited by the small, episodic impetigo market, inexpensive generic alternatives, short treatment duration and limited public financial disclosure.

No audited revenue series for XEPI has been publicly reported. The product is not separately identified in the public financial reporting of its commercial partners, so its sales trajectory must be assessed through market structure, product positioning, regulatory milestones and competitive conditions rather than confirmed brand revenue.

What is XEPI and what market does it address?

XEPI is a topical nonfluorinated quinolone antibiotic.

Attribute	XEPI data
Active ingredient	Ozenoxacin
Strength	1% cream
Dosage form	Topical cream
FDA indication	Impetigo due to susceptible S. aureus or S. pyogenes
Approved age	Two months and older
Approved dosing	Apply a thin layer twice daily for five days
FDA approval	December 2017
Regulatory application	NDA 209501
Commercial category	Prescription topical anti-infective
Primary competitors	Generic mupirocin, retapamulin, antiseptic and nonprescription wound-care products

The label positions XEPI for localized bacterial skin infection rather than chronic dermatology. That limits refill frequency and reduces the lifetime value of each treated patient. A standard course is five days, which creates a rapid prescription cycle but little repeat-purchase revenue.[2]

How large is the XEPI market?

The addressable market is the U.S. outpatient impetigo market, not the broader dermatology market. Impetigo is common in children, but treatment is usually short and often managed with inexpensive topical antibiotics. Market volume therefore does not translate directly into brand revenue.

The principal commercial constraints are:

1. Generic mupirocin is widely recognized by prescribers and pharmacies.
2. Many cases are treated empirically without bacterial culture.
3. Payers often place branded topical antibiotics on unfavorable formulary tiers.
4. Physicians may reserve newer products for cases involving treatment failure, adherence concerns or resistance considerations.
5. The product has no chronic-use indication that would generate recurring prescriptions.

XEPI’s commercial rationale depends on differentiation from established topical therapies. Ozenoxacin is a nonfluorinated quinolone, which distinguishes it pharmacologically from older topical agents. That distinction has limited practical value when a payer or prescriber views a five-day course of generic mupirocin as adequate.

What is the financial trajectory of XEPI?

Public sources do not report standalone XEPI revenue, prescription volume, gross margin or operating profit. The product is commercially immaterial at the reporting scale of its corporate partners or is included within broader dermatology and prescription-product categories.

Financial metric	Publicly reported XEPI figure
Annual net sales	Not separately disclosed
Quarterly sales	Not separately disclosed
Prescription volume	Not separately disclosed
Commercial gross margin	Not separately disclosed
Sales force spending	Not separately disclosed
Royalty rate	Not publicly disclosed
Product acquisition value	Not established from cited public sources

The financial trajectory is therefore best characterized as a niche branded-product profile:

• Initial launch opportunity after FDA approval in 2017.
• Early commercial adoption constrained by generic topical antibiotics.
• Limited potential for strong recurring revenue because treatment lasts five days.
• Potential price and access pressure as payers compare XEPI with generic mupirocin.
• Low visibility of the product in consolidated financial reporting.
• Limited evidence of a major expansion into adjacent indications.

The most important economic variable is not clinical demand alone. It is the ability to secure favorable reimbursement and persuade prescribers that ozenoxacin provides sufficient value over inexpensive alternatives.

Who markets XEPI?

XEPI was developed by Ferrer Internacional, S.A. U.S. commercial materials and prescribing information have identified commercial distribution or marketing arrangements involving U.S. dermatology-focused partners, including Cutanea Life Sciences and later commercial entities associated with Ferrer’s U.S. operations. Publicly available product materials should be checked against current National Drug Code and DailyMed records for the active distributor.[2]

The commercial model has relied on licensing, distribution and specialty-pharmaceutical promotion rather than the scale of a major primary-care antibiotic franchise. That structure can reduce fixed infrastructure costs, but it also limits reach across pediatricians, family physicians and urgent-care clinics.

What competitive drugs limit XEPI growth?

XEPI versus mupirocin

Mupirocin is the main commercial comparator. It is available as a low-cost generic ointment and cream and has extensive prescribing familiarity. Mupirocin’s advantages include price, formulary access and established use in localized skin infections. XEPI’s advantages include a newer mechanism, cream formulation and a positioning strategy based on avoiding certain resistance concerns associated with older agents.

The commercial problem is that these advantages may not justify a branded acquisition cost for uncomplicated impetigo.

XEPI versus retapamulin

Retapamulin is another topical prescription antibiotic with an impetigo indication. Its market presence is smaller than mupirocin’s, and it also faces the limitations of a short-course topical product. XEPI competes against retapamulin on formulation, clinical positioning and prescriber familiarity, but both products face generic and reimbursement pressure.

XEPI versus oral antibiotics

For extensive disease, bullous impetigo or cases involving multiple lesions, clinicians may choose oral therapy. XEPI is therefore concentrated in localized cases where the patient and prescriber prefer topical treatment.

What FDA exclusivity did XEPI receive?

XEPI received FDA approval under the new drug application pathway. The approval did not create biologic exclusivity because ozenoxacin is a small-molecule drug, not a biologic.

The product’s principal regulatory protection was a period of new clinical investigation exclusivity associated with the approval. That exclusivity was limited in duration and did not create a long-term barrier comparable to a composition-of-matter patent. FDA approval itself did not prevent generic competition after all applicable regulatory and patent barriers expired.[1]

FDA protection	Assessment
New chemical entity exclusivity	Not identified as the principal protection
New clinical investigation exclusivity	Applicable to qualifying approval studies
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	No separate six-month extension identified
Biologic exclusivity	Not applicable
Pediatric indication	Included in the approved label

What patents protect XEPI?

XEPI’s intellectual-property position is based on patents covering ozenoxacin, pharmaceutical compositions, formulations and methods of treating bacterial skin infections. The commercial value of those patents depends on claim scope, terminal disclaimers, patent-term adjustments, Orange Book listing and whether any listed patents remain enforceable against an ANDA applicant.

The relevant patent categories are:

• Ozenoxacin compound and chemical forms.
• Topical compositions containing ozenoxacin.
• Methods of treating impetigo and bacterial skin infections.
• Manufacturing and formulation processes.
• Drug product specifications and delivery characteristics.

A definitive patent-expiration table requires a current FDA Orange Book record and prosecution-history review. Public product materials alone do not establish the enforceable expiration date of every patent associated with XEPI. The FDA Orange Book is the controlling commercial reference for listed patents tied to an approved drug application.[3]

Orange Book status

Question	XEPI assessment
FDA-approved drug application	Yes, NDA 209501
Orange Book-listed product	Expected for an approved prescription drug, subject to current FDA listing
Paragraph IV litigation	No major publicly established Paragraph IV case is identified in the cited sources
Patent-term extension	No confirmed extension is identified here
Authorized generic	No publicly confirmed authorized-generic launch identified
Biosimilar pathway	Not applicable

When does XEPI lose exclusivity?

XEPI’s regulatory exclusivity period has already expired. Any continuing commercial protection depends on patent claims, formulation patents, regulatory filing timing and the absence of successful generic challenges.

Because the drug is a topical semisolid, generic applicants may face product-equivalence and bioequivalence requirements that are more complex than those for a simple oral tablet. FDA review may consider formulation sameness, pharmaceutical equivalence, local availability and the applicable topical-product pathway. These requirements can delay entry, but they do not create durable protection if a generic applicant can satisfy FDA standards.

Which companies are challenging XEPI?

No major publicly established Paragraph IV litigation or settlement agreement involving XEPI is identified in the cited FDA and product sources. The absence of a prominent public challenge does not prove that no ANDA activity exists. ANDA filings, patent certifications and commercial settlement terms are often difficult to track until litigation is filed or the FDA publishes relevant approval information.

The most plausible generic entrants would be manufacturers already active in topical dermatology and anti-infective products. Likely competitive capabilities include:

• Semisolid formulation development.
• FDA ANDA or applicable 505(b)(2) experience.
• Retail and specialty-pharmacy distribution.
• Existing contracts for generic mupirocin or other topical antibiotics.
• Capacity to manage manufacturing-site inspection and product-quality requirements.

What generic launch risks exist for XEPI?

Generic entry would likely produce rapid price erosion because the product has:

• A short treatment duration.
• Limited brand loyalty.
• A readily recognized generic comparator.
• No chronic maintenance use.
• Low switching friction at the pharmacy level.
• Limited evidence of a large specialty-practice moat.

The launch impact would depend on whether a generic is therapeutically substitutable at the pharmacy, whether payers place it on a preferred tier and whether the branded product retains exclusive contracts or physician-support programs.

A first generic could take share quickly if priced below XEPI and supported by major pharmacy benefit managers. Multiple entrants would increase the probability of substantial net-price compression.

How strong is the XEPI patent estate?

XEPI’s patent estate appears commercially weaker than the estate of a systemic drug protected by a broad composition patent and multiple approved indications. Its value rests heavily on topical formulation and method claims, which can be narrower and easier to design around than a broad compound claim.

The estate may still delay generic entry if:

• A formulation patent covers the marketed cream.
• The generic must demonstrate equivalence to a protected formulation.
• The listed patents have meaningful remaining term.
• The sponsor brings timely litigation after a Paragraph IV notice.
• Manufacturing or analytical requirements create development costs.

The absence of a large, visible litigation record reduces evidence of a high-value patent barrier. It also suggests that expected market value may not justify extensive litigation spending unless generic entry threatens a larger-than-publicly recognized revenue stream.

What manufacturing and intellectual-property barriers affect XEPI?

The principal technical barriers are formulation reproducibility, control of particle size or drug distribution, preservative performance, microbiological quality and manufacturing consistency for a topical cream. These barriers can affect generic development but are usually manageable for experienced dermatology manufacturers.

Manufacturing risk is more relevant to product quality and launch timing than to long-term exclusivity. A generic company with an established semisolid manufacturing platform could reduce development costs and shorten the path to market.

Does XEPI have biosimilar risk?

No. XEPI contains ozenoxacin, a small-molecule active ingredient. It is exposed to generic-drug risk, not biosimilar competition. Any follow-on product would generally be evaluated through an abbreviated or alternative small-molecule pathway rather than the Public Health Service Act biosimilar pathway.

What is the outlook for XEPI?

XEPI’s commercial outlook is constrained but defensible in a narrow segment. The product can retain value where prescribers prioritize a newer topical antibiotic, a cream formulation, or an alternative to older agents. Its ceiling is limited by the short treatment course, low disease severity in many cases, generic substitution and payer economics.

The most likely financial trajectory is stable-to-declining niche revenue rather than material growth. Upside would require one of four developments:

1. Stronger evidence of clinical or resistance-related differentiation.
2. Expanded use beyond uncomplicated impetigo.
3. Improved formulary placement.
4. A commercial transaction that adds distribution scale without materially increasing selling costs.

Absent those developments, XEPI is more likely to remain a focused dermatology asset than become a major pharmaceutical franchise.

Key Takeaways

• XEPI is ozenoxacin 1% cream, FDA-approved in 2017 for impetigo in patients aged two months and older.
• The product competes primarily with generic mupirocin and, to a lesser extent, retapamulin and oral antibiotics.
• No standalone public revenue or profit data are available for XEPI.
• The product’s five-day treatment course limits recurring revenue and lifetime patient value.
• Regulatory exclusivity has expired; current protection depends on remaining patent and formulation rights.
• No major publicly established Paragraph IV litigation or settlement is identified in the cited sources.
• XEPI faces generic rather than biosimilar risk.
• Its financial outlook is a constrained niche franchise with meaningful price and formulary exposure.

FAQs

Is XEPI still FDA-approved?

Yes. XEPI remains associated with FDA-approved NDA 209501 for topical treatment of impetigo caused by susceptible S. aureus or S. pyogenes.

Is ozenoxacin the same as mupirocin?

No. Ozenoxacin and mupirocin are different topical antibiotics with different chemical structures and mechanisms. Mupirocin is generally available as a low-cost generic, while XEPI is a branded ozenoxacin product.

Can pharmacies automatically substitute generic mupirocin for XEPI?

No. Automatic substitution depends on state law, prescription wording, product equivalence and payer rules. Mupirocin is a therapeutic alternative, not the same active ingredient as ozenoxacin.

Is XEPI used for acne or rosacea?

The FDA-approved indication is impetigo. Use for acne, rosacea or other skin conditions would be outside the approved label unless separately authorized.

What is the biggest commercial risk to XEPI?

The largest risk is substitution by inexpensive generic topical antibiotics, particularly mupirocin, combined with unfavorable formulary placement and limited repeat use.

References

1. U.S. Food and Drug Administration. (2017). FDA approves new drug for treatment of impetigo.
2. DailyMed. (n.d.). XEPI- ozenoxacin cream: Prescribing information. National Library of Medicine.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.